Cell4D is developing ‘fingerprinting’ technology for live cells using mechanomics, a discipline sitting at the intersection of biology and biomechanics. This biomarker that is used to screen and sort live cells for cell therapies.
Global pharma is hitting a major fork in the road, and one way leads to failure. For me, it’s vital that the industry comes together to grasp the once-in-a-generation opportunity that emergent technology is offering.
Founders of early-stage start-ups are passionate, driven and optimistic. So, as they embark on the mission to sell their vision, they should accentuate the positive and keep negative thoughts of risk to the back of their mind, right? Wrong.
AI-based methods are offering superhuman image enhancement. But their medical applications are not without risk – unless, that is, you consider a hybrid approach.
Decarbonising aviation is a herculean task, but the HBx organism holds the potential to radically change both the carbon intensity of transport fuels and the economics of the biofuel industry.